MobilEye Global Inc vs McKesson Corporation — how do they compare? MobilEye Global Inc trades at $8.87 (market cap $7.54B), while McKesson Corporation trades at $878 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 13.9× MobilEye Global Inc's market cap, and McKesson Corporation pays a 0.42% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| MBLY | MCK | |
|---|---|---|
Market Cap | $7.54B | $105.14B |
Sector | Technology | Health |
52-Week High | $15.54 | $995.69 |
52-Week Low | $6.56 | $659.01 |
Enterprise Value | $6.10B | $111.67B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.80, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $0.19 versus $0.06 expected, driven by an R&D grant, while revenue reached $508 million (Bloomberg, 2026-07-23). The company faces leadership transition as CEO Amnon Shashua steps down after 27 years, amid expanded robotaxi and ADAS initiatives, including a new supply deal with Stellantis (Business Wire, 2026-07-21).
Outlook: Analyst consensus is bullish with a $11.40 price target (61.5% buy ratings), but risks include persistent net losses (-$4.1B in 2026), high EV/EBITDA of 43.25, and execution challenges under new leadership. The stock offers upside if robotaxi adoption accelerates, but profitability concerns and market volatility pose headwinds.
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
Trailing returns across standard periods
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →